NCT03802084View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

March 26, 2024

Study Completion Date

March 26, 2024

Conditions
Desmoid Tumor
Interventions
DRUG

vactosertib/imatinib combination

"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~* 1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"

Trial Locations (1)

03722

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

Hyo Song Kim

OTHER

NCT03802084 - A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor | Biotech Hunter | Biotech Hunter